Advocacy is at the heart of patient care

Patients trust your knowledge and insights.

In fact, nurses received the highest ethics ratings—far more than any of the other 17 professions rated.1

In fact, nurses received the highest ethics ratings—far more than any of the other 17 professions rated.1

79% of US adults said that nurses have “very high” or “high” levels of honesty and ethical standards.1,*

*Results for this Gallup poll are based on telephone interviews conducted November 9 to December 2, 2022, with a random sample of 1020 adults, aged 18 years and older, living in all 50 US states and the District of Columbia.1 Survey participants were asked “Please tell me how you would rate the honesty and ethical standards of people in these different fields—very high, high, average, low, or very low?”1

We have the information and tools you need to help guide your discussions with patients about vaccination

Create Meaningful Connections

Each shingles experience is personal—that’s why understanding risk factors, its impact, and its potential complications is so critical.

Care With Confidence

The decision to vaccinate is important. Learn important facts about SHINGRIX so you feel confident in the discussion.

Lead the Conversation

Discover resources to strengthen your knowledge and to help guide the conversation with your patients.

Create Meaningful Connections

You have the power to make a difference in your patients’ lives

Shingles usually presents as a painful, unilateral, blistering rash that lasts 7 to 10 days and can take 2 to 4 weeks to heal2

Shingles can lead to serious and long-lasting complications,† including2:

Postherpetic neuralgia (PHN)

Nerve pain, in the area where the rash was, that lasts months (≥90 days), but can sometimes last years2,3

Visual complications

Affects between 10% and 25% of individuals with shingles2
Can lead to ophthalmic complications, such as vision loss in rare cases2

†SHINGRIX is not indicated for the prevention of PHN or other complications.3

Nearly everyone ≥50 years of age is at risk for shingles2,4,5

Shingles is caused by the same virus as chickenpox, the varicella zoster virus (VZV).2 After a person recovers from chickenpox, the virus stays dormant in the body and can reactivate later in life causing shingles.2 More than 99.5% of people 50 years and older are infected with VZV.2,4 In 1 out of 3 people, the dormant virus reactivates and causes shingles.2

Age-related decline in immunity is a dominant driver of shingles2,6,7

Increasing age causes a natural decline in immunity2
As immune function declines, there is a reduction in the number and functionality of immune cells that prevent reactivation of VZV2,6-10
Age-related decline in immunity leads to a sharp increase in the incidence and complications of shingles2,6

Care With Confidence

Shingles prevention is possible with SHINGRIX

SHINGRIX: Recommended by CDC for the prevention of shingles11

The CDC states SHINGRIX is:

Recommended for the prevention of herpes zoster and related complications for immunocompetent adults aged ≥50 years
Recommended for the prevention of herpes zoster and related complications for immunocompetent adults who previously received zoster vaccine live (ZVL)

SHINGRIX is not indicated for the prevention of herpes zoster related complications.3

Only SHINGRIX delivered >90% efficacy against shingles regardless of age in those 50 years and older.3,‡

It is important to inform patients that they may experience adverse reactions after receiving SHINGRIX. In clinical trials, the most common adverse reactions were pain, redness, swelling at the injection site, muscle pain, fatigue, headache, shivering, fever, and upset stomach. These adverse reactions had a median duration of 2 to 3 days.3

‡Data from the phase 3 ZOE-50 (≥50 years of age) trial (median follow-up period 3.1 years) and pooled data in individuals ≥70 years of age from the phase 3 ZOE-50 and ZOE-70 trials (median follow-up period 4 years) in subjects who received 2 doses of SHINGRIX (n=7344 and 8250, respectively) or placebo (n=7415 and 8346, respectively). These populations represented the modified Total Vaccinated Cohort, defined as patients who received 2 doses (0 and 2 months) of either SHINGRIX or placebo and did not develop a confirmed case of herpes zoster within 1 month after the second dose. See study designs on the Efficacy page for details.3,12

SHINGRIX is a vaccine for intramuscular injection only.3

SHINGRIX is administered as a 2-dose series: The second dose should be administered anytime between 2 and 6 months after the first dose.3

Recommend with certainty: SHINGRIX is now $0 for most patients 50 years and older13-15,§

Due to the Inflation Reduction Act, all Medicare Part D patients can get SHINGRIX for $0 through their pharmacy13,14
More than 9 out of 10 patients with commercial insurance plans are covered, with average copays of just $4 or less, while 95% of commercial patients pay $0 for SHINGRIX13,15,ǁ

§Coverage and cost may vary and are subject to change without notice. Reimbursement decisions are made by individual insurance plans.

ǁSOURCE: Managed Markets Insight & Technology, LLC, Database as of October 2022. Coverage represents access to reimbursement from a health plan with restrictions appropriate to the Advisory Committee on Immunization Practices (ACIP) recommendation(s) and/or prescribing information. Veterans Affairs (VA) and Indian Health Service (IHS) lives have been omitted when calculating the percentage of lives.

Lead the Conversation

You have the power to be one of your patients’ biggest advocates.

The best conversation starts with the right information.

Designed to help educate and communicate the importance of shingles vaccination, the following resources can be used to help turn each conversation into shingles prevention.

DISCUSSION GUIDE

This valuable aid will help you and other office staff counsel patients before vaccination.

Read Now

SECOND DOSE REMINDER CARD

This physical card will help your patients keep track of their second dose appointment with a QR code and written scheduling reminder.

Read Now

VACCINE SCHEDULER/
LOCATOR TOOL:

Help your patients quickly schedule their vaccination.

Schedule Now

Indication & Important Safety Info

Indication

SHINGRIX is a vaccine indicated for prevention of herpes zoster (HZ) (shingles):

in adults aged 50 years and older.
in adults aged 18 years and older who are or will be at increased risk of HZ due to immunodeficiency or immunosuppression caused by known disease or therapy.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

SHINGRIX is a vaccine indicated for prevention of herpes zoster (HZ) (shingles):

in adults aged 50 years and older.
in adults aged 18 years and older who are or will be at increased risk of HZ due to immunodeficiency or immunosuppression caused by known disease or therapy.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

SHINGRIX is a vaccine indicated for prevention of herpes zoster (HZ) (shingles):

in adults aged 50 years and older.
in adults aged 18 years and older who are or will be at increased risk of HZ due to immunodeficiency or immunosuppression caused by known disease or therapy.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

Important Safety Information

SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX
Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX

SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX
Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX

SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX
Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX
In a postmarketing observational study, an increased risk of Guillain-Barré syndrome was observed during the 42 days following vaccination with SHINGRIX
Syncope (fainting) can be associated with the administration of injectable vaccines, including SHINGRIX. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
Solicited local adverse reactions reported in individuals aged 50 years and older were pain (78%), redness (38%), and swelling (26%)
Solicited general adverse reactions reported in individuals aged 50 years and older were myalgia (45%), fatigue (45%), headache (38%), shivering (27%), fever (21%), and gastrointestinal symptoms (17%)
Solicited local adverse reactions reported in autologous hematopoietic stem cell transplant recipients (aged 18 to 49 and ≥50 years of age) were pain (88% and 83%), redness (30% and 35%), and swelling (21% and 18%)
Solicited general adverse reactions reported in autologous hematopoietic stem cell transplant recipients (aged 18 to 49 and ≥50 years of age) were fatigue (64% and 54%), myalgia (58% and 52%), headache (44% and 30%), gastrointestinal symptoms (21% and 28%), shivering (31% and 25%), and fever (28% and 18%)
The data are insufficient to establish if there is vaccine-associated risk with SHINGRIX in pregnant women
It is not known whether SHINGRIX is excreted in human milk. Data are not available to assess the effects of SHINGRIX on the breastfed infant or on milk production/excretion
Vaccination with SHINGRIX may not result in protection of all vaccine recipients

Advocacy is at the heart of patient care

Patients trust your knowledge and insights.

In fact, nurses received the highest ethics ratings—far more than any of the other 17 professions rated.1

In fact, nurses received the highest ethics ratings—far more than any of the other 17 professions rated.1

You can use this dynamic to discuss vaccination

We have the information and tools you need to help guide your discussions with patients about vaccination

Create Meaningful Connections

You have the power to make a difference in your patients’ lives

Shingles usually presents as a painful, unilateral, blistering rash that lasts 7 to 10 days and can take 2 to 4 weeks to heal2

Shingles can lead to serious and long-lasting complications,† including2:

Nearly everyone ≥50 years of age is at risk for shingles2,4,5

Age-related decline in immunity is a dominant driver of shingles2,6,7

Age-related decline in immunity is a dominant driver of shingles2,6,7

You can start the vaccination conversation today

Care With Confidence

Shingles prevention is possible with SHINGRIX

SHINGRIX: Recommended by CDC for the prevention of shingles11

The CDC states SHINGRIX is:

The CDC states SHINGRIX is:

Recommend with certainty: SHINGRIX is now $0 for most patients 50 years and older13-15,§

Recommend with certainty: SHINGRIX is now $0 for most patients 50 years and older13-15,§

You can use this dynamic to discuss vaccination

Lead the Conversation

You have the power to be one of your patients’ biggest advocates.

The best conversation starts with the right information.

Designed to help educate and communicate the importance of shingles vaccination, the following resources can be used to help turn each conversation into shingles prevention.